Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,750
  • Shares Outstanding, K 5,032
  • Annual Sales, $ 53,940 K
  • Annual Income, $ -10,440 K
  • 60-Month Beta 2.20
  • Price/Sales 0.64
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.49
  • Number of Estimates 1
  • High Estimate -0.49
  • Low Estimate -0.49
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +18.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.24 +20.42%
on 07/08/20
8.06 -21.71%
on 08/05/20
+0.59 (+10.31%)
since 07/07/20
3-Month
4.52 +39.60%
on 06/15/20
8.06 -21.71%
on 08/05/20
+0.49 (+8.42%)
since 05/07/20
52-Week
2.86 +120.61%
on 03/19/20
10.35 -39.03%
on 09/24/19
-1.79 (-22.10%)
since 08/07/19

Most Recent Stories

More News
Global Ocular Inflammation Treatment Market 2020 With COVID-19 Update, Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2026

A recent report provides crucial insights along with application based and forecast information in the Global Ocular Inflammation Treatment Market. The report provides a comprehensive analysis of key factors...

AKRX : 0.0900 (-51.01%)
ALIM : 6.31 (-8.28%)
AGN : 193.02 (+0.02%)
NVS : 82.91 (-0.60%)
PFE : 38.45 (+0.47%)
VRX.TO : 30.80 (-3.33%)
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

EBS : 130.66 (+2.91%)
ALIM : 6.31 (-8.28%)
AERI : 12.61 (+4.21%)
ACIU : 6.72 (+1.82%)
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

AMAG : 10.55 (+5.08%)
EBS : 130.66 (+2.91%)
ALIM : 6.31 (-8.28%)
ACIU : 6.72 (+1.82%)
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

EBS : 130.66 (+2.91%)
HZNP : 76.06 (+5.32%)
ALIM : 6.31 (-8.28%)
ACAD : 42.73 (-2.06%)
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

EBS : 130.66 (+2.91%)
HZNP : 76.06 (+5.32%)
ALIM : 6.31 (-8.28%)
ACIU : 6.72 (+1.82%)
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

ZTS : 158.88 (-1.52%)
EBS : 130.66 (+2.91%)
ALIM : 6.31 (-8.28%)
ACIU : 6.72 (+1.82%)
What Makes Alimera Sciences (ALIM) a New Strong Buy Stock

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ALIM : 6.31 (-8.28%)
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 5.41 (+21.03%)
ACU : 22.49 (+2.23%)
AEY : 2.37 (+2.60%)
ADIL : 1.8600 (-3.12%)
ADXS : 0.5500 (-3.44%)
AEHR : 2.12 (-6.05%)
AIM : 2.99 (+2.40%)
AIRI : 1.2700 (-4.51%)
KERN : 6.55 (-1.65%)
ALIM : 6.31 (-8.28%)
ALLT : 11.55 (+0.70%)
AMS : 2.16 (+0.93%)
ANVS : 5.55 (-2.12%)
APEN : 1.5000 (-7.41%)
APM : 3.54 (-0.28%)
AQB : 2.51 (-17.97%)
ARTL : 1.2499 (-0.01%)
ARHH : 0.7000 (-7.89%)
ATOM : 11.84 (-5.28%)
ATOS : 3.83 (-0.78%)
ACU.VN : 0.115 (unch)
AUTO : 1.7500 (-1.69%)
AYRO : 4.17 (-2.80%)
AYTU : 1.3800 (-0.72%)
AZRX : 1.1700 (+7.34%)
BLDP : 14.74 (-1.11%)
BELFA : 12.88 (+2.98%)
BCDA : 2.67 (-1.84%)
BIOC : 1.0100 (-11.40%)
BMRA : 8.81 (-0.68%)
BSGM : 7.43 (-2.49%)
BLNK : 11.85 (-2.67%)
BKEP : 1.4300 (unch)
CLBS : 2.44 (+4.72%)
CLXT : 5.59 (+7.50%)
ASUR : 7.31 (-0.27%)
BLGO : 0.1750 (-1.41%)
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ALIM : 6.31 (-8.28%)
Alimera Sciences: 2Q Earnings Snapshot

ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $2.5 million in its second quarter.

ALIM : 6.31 (-8.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade ALIM with:

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

2nd Resistance Point 7.27
1st Resistance Point 6.79
Last Price 6.31
1st Support Level 5.98
2nd Support Level 5.65

See More

52-Week High 10.35
Fibonacci 61.8% 7.49
Fibonacci 50% 6.61
Last Price 6.31
Fibonacci 38.2% 5.72
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar